DUBLIN, and PRAGUE, Czech Republic, April 19, 2006-Alltracel Pharmaceuticals Plc., (“Alltracel”, or “the Company”), (AIM:AP.L), the Medical Technology Company focused on the Woundcare, Oralcare and Cardiovascular Health markets is pleased to report on the successful completion of the statin and Alltracel bioactive combination pre-clinical studies. These trials which took place over the past six months at the Faculty of Pharmacy at Charles University in the Czech Republic; were a follow on to the published* trial results, reported in March 2005, that confirmed the potential for complementary cardiovascular benefits of the combination of statins and Alltracel’s bioactive.
